DCA (Sodium dichloroacetate)

Catalog No.S8615 Batch:S861506

Print

Technical Data

Formula

C2HCl2O2.Na
Molecular Weight 150.92 CAS No. 2156-56-1
Solubility (25°C)* In vitro DMSO 30 mg/mL (198.78 mM)
Water 30 mg/mL (198.78 mM)
Ethanol 30 mg/mL (198.78 mM)
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
Targets
PDK4 [4]
(Cell-free assay)		 PDK2 [4]
(Cell-free assay)
80 μM 183 μM
In vitro DCA can trigger apoptosis of human lung, breast and brain cancer cells[1]. After DCA treatment, cancer cells shows increased levels of ROS, depolarization of the MMP in vitro and increased apoptosis both in vitro and in vivo[2]. DCA inhibits the activity of pyruvate dehydrogenase kinase (PDK), thereby stimulating the mitochondrial enzyme pyruvate dehydrogenase (PDH). When turned off, PDH no longer converts pyruvate to acetyl-CoA required for mitochondrial respiration and glucose dependent oxidative phosphorylation. DCA thus shifts cellular metabolism from glycolysis to glucose oxidation, decreasing the mitochondrial membrane potential gradient and helping to open mitochondrial transition pores. This metabolic switch facilitates translocation of pro-apoptotic mediators like cytochrome c (cyt c) and apoptosis inducing factor (AIF), both of which stimulate apoptosis. DCA thereby drives cancer cells to commit suicide by apoptosis[3].
In vivo DCA can act as a cytostatic agent in vitro and in vivo, without causing apoptosis (programmed cell death). DCA is discovered to be a safe drug with no cardiac, pulmonary, renal or bone marrow toxicity. The most serious common side effect consists of peripheral neuropathy, which is reversible. DCA has anti-cancer activity in several cancer types including colon, prostate, ovarian, neuroblastoma, lung carcinoid, cervical, endometrial, cholangiocarcinoma, sarcoma and T-cell lymphoma. Other antineoplastic actions of DCA have also been suggested. These include angiogenesis blockade, changes in expression of HIF1-α, alteration of pH regulators V-ATPase and MCT1, and other cell survival regulators such as PUMA, GLUT1, Bcl2 and p53. DCA is able to significantly reduce metastatic burden in the lungs of rats in a highly metastatic in vivo model of breast cancer[1]. In vivo the DCA-Na treatment induces 20% survival and decreased the tumoral diameter, volume and weight, without affect the body weight and avoid metastasis in C57BL/6 mice[3].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    breast cancer cell

  • Concentrations

    5 mM

  • Incubation Time

    24-72 h

  • Method

    For the assessment of cell viability, cells are plated in 96 well plates at a density of 3000 cells per well and 8 wells per group. Following exposure to DCA and ATO for 24 to 72 hours, cells are incubated for 3 hours with neutral red (30 μg/ml) in fresh media, then washed with PBS, followed by the addition of lysis buffer (acetic acid/methanol, 80%/20%) and the absorbance at 540 nm is recorded. Results are expressed as mean ± S.D, calculations are performed using the Prism software package, ANOVA with Tukey post test was applied and P < 0.05 was considered to be statistically significant.
Animal Study:

[3]
  • Animal Models

    C57BL/6 mice

  • Dosages

    500 and 1000 mg/kg

  • Administration

    i.p.

Selleck's DCA (Sodium dichloroacetate) has been cited by 17 publications

Decreased AMPK/SIRT1/PDK4 induced by androgen excess inhibits human endometrial stromal cell decidualization in PCOS [ Cell Mol Life Sci, 2024, 81(1):324] PubMed: 39080028
HIF-1α protects nucleus pulposus cells from oxidative stress-induced mitochondrial impairment through PDK-1 [ Free Radic Biol Med, 2024, 224:39-49] PubMed: 39128487
Proteomic analysis identifies PFKP lactylation in SW480 colon cancer cells [ iScience, 2024, 27(1):108645] PubMed: 38155775
Analysis of GCRV Pathogenesis and Therapeutic Measures Through Proteomic and Metabolomic Investigations in GCRV-Infected Tissues of Grass Carp (Ctenopharyngodon idella) [ Int J Mol Sci, 2024, 25(21)11852] PubMed: 39519403
A simplified herbal decoction attenuates myocardial infarction by regulating macrophage metabolic reprogramming and phenotypic differentiation via modulation of the HIF-1α/PDK1 axis [ Chin Med, 2024, 19(1):75] PubMed: 38816815
PDHA1 hyperacetylation-mediated lactate overproduction promotes sepsis-induced acute kidney injury via Fis1 lactylation [ Cell Death Dis, 2023, 14(7):457] PubMed: 37479690
Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis [ Nat Commun, 2022, 13(1):1417] PubMed: 35304872
Vps33B controls Treg cell suppressive function through inhibiting lysosomal nutrient sensing complex-mediated mTORC1 activation [ Cell Rep, 2022, 39(11):110943] PubMed: 35705052
Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases [ Mol Oncol, 2022, 16(1):219-249] PubMed: 34058053
Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers [ Exp Dermatol, 2022, 31(10):1477-1499] PubMed: 35913427

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.